Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.39 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | CCR3 | P51677 | 11/20 | 0.36 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14392772 | 1.00 | DGAT2 (0.39) | DGAT2VNN1CCR3EGLN1 | |
| SCHEMBL14368773 | 0.86 | HPGDS (0.41) | CCR3EGLN1 | |
| SCHEMBL5661805 | 0.85 | HPGDS (0.47) | DGAT2EGLN1 | |
| SCHEMBL5661625 | 0.78 | HRH2 (0.41) | VNN1CCR3 | |
| SCHEMBL5669369 | 0.78 | HRH2 (0.41) | VNN1CCR3 | |
| SCHEMBL5669362 | 0.78 | HRH2 (0.41) | VNN1CCR3 | |
| SCHEMBL14392360 | 0.78 | HRH2 (0.41) | VNN1CCR3 | |
| SCHEMBL5662634 | 0.75 | CCR3 (0.40) | CCR3 | |
| SCHEMBL4426712 | 0.73 | ACKR3 (0.47) | EGLN1 | |
| SCHEMBL14368706 | 0.73 | ACKR3 (0.47) | EGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259888-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259888-A1 | Novel Compounds | OPRL1, OPRM1, SIGMAR1 | DGAT2 4460/4885VNN1 4189/4885CCR3 247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.